Key insights
- An analyst suggests buying SIBN, a small-cap medical device company, citing steady business, 15% topline growth, and a potential acquisition target. The analyst believes the stock is undervalued based on a 5x gross profit multiple. The strategy is opportunistic, aiming to buy low and sell high, rather than a long-term investment. The positive ROIC trend is a bullish signal.
I have been following this company since the IPO. The business has been steady, but the stock bounces around between $12 and $20. Time to buy this here.
15% topline growth. $500MM EV, no debt. These young medical device companies spend a lot on building the sales force, educating surgeons in the new device. I have watched this cycle many times.
These small ortho companies always have a good chance of being acquired. 5x gross profit would be the bare minimum price = $23 vs $13.70 today. I am not saying a deal is imminent.
I have owned this a few times, buying at $13ish, sell at $17-18. Very good risk to reward trade-off. 2026 revenue estimates steadily rising. ROIC trending the right way, probably inflects positive in 2026.
This is NOT a buy and hold forever. This is buy right, sell right. Small caps rarely become large caps. You have to invest opportunistically.